Harnessing the power of interleukin-10,
master anti-inflammatory cytokine
OUR UNIQUE APPROACH
200 million worldwide suffer from chronic inflammatory diseases. There is a large unmet need for treatments for chronic inflammatory disease that are efficacious and safe. Xalud Therapeutics is developing a non-viral gene therapy targeting immune modulation. Our mission is to harness the power of interleukin-10 (IL-10), a potent anti-inflammatory cytokine, to address the root cause of inflammation and subsequently restore homeostasis in the immune system.
A healthy, strong body lives in a state of equilibrium. Every day, it detects signals of injury or chronic disease progression and naturally restores itself by modulating anti-inflammatory cytokines and pro-inflammatory mediators. When the body is unbalanced, unfortunately, inflammation can flare and persist over long periods of time. This results in a myriad of diseases and associated symptoms like debilitating pain that prevents millions from living healthy productive lives.
Xalud Therapeutics aims to break this cycle of chronic, pathologic inflammation. Instead of masking, we help the body to restore the natural balance of inflammatory and restorative pathways by adding back one of its own defenses to increase anti-inflammatory signals.
IL-10 is a potent anti-inflammatory cytokine that inhibits and counterbalances effects of inflammatory cytokines. Insufficient IL-10 expression or signaling have been implicated in inflammation and numerous immune disease states. Our breakthrough therapeutic candidate, XT-150, addresses pathologic inflammation by expressing IL-10 locally to the sites of inflammation. Xalud is currently evaluating XT- 150 across multiple indications in preclinical and clinical studies.
Degenerative Disc Disease
Ophthalmic, Gastrointestinal, Dermal
PRE-CLINICAL IND-ENABLING PHASE 1/2 PHASE 2/3
Chairman and CEO | PBM Capital
President | PBM Capital
JAYSON RIEGER, PHD, MBA
Operations | PBM Capital
Investor Relations | PBM Capital
Manufacturing | PBM Capital
John Forsayeth, PhD Linda Watkins, PhD Tarek Samad, PhD
Lee Simon, MD, FACP FACR Nathaniel Katz, MD Eric Grigsby, MD Leonardo Kapura, MD